Login to Your Account



Pharma: Other news to note


Monday, February 24, 2014
Teva Pharmaceutical Industries Ltd., of Jerusalem, said the European Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for Duoresp Spiromax (budesonide and formoterol fumarate dehydrate) inhalation powder for the treatment of patients with asthma and chronic obstructive pulmonary disease when a combination inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription